OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study

Trial Profile

OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Headache
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2016 Status changed from recruiting to discontinued.
    • 28 Dec 2015 Planned End Date changed from 1 Sep 2014 to 1 Sep 2016, according to ClinicalTrials.gov record.
    • 28 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Sep 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top